Navigation Links
Targeting nicotine receptors to treat cognitive impairments in schizophrenia
Date:1/11/2011

Smoking is a common problem for patients with schizophrenia. The increased tendency of patients diagnosed with this disorder is to not only smoke, but to do so more heavily than the general public. This raises the possibility that nicotine may be acting as a treatment for some symptoms of schizophrenia.

Nicotine acts through two general classes of brain receptors, those with high and low affinity for nicotine. The low affinity class of nicotinic receptors contains the alpha-7 subunit, which is present in reduced numbers in people with schizophrenia.

Two papers published in the January 1st issue of Biological Psychiatry suggest that drugs that stimulate these alpha-7 subunit-containing nicotinic receptors might enhance cortical function and treat cognitive impairments associated with schizophrenia.

In their study of healthy monkeys, Graham Williams and colleagues at Yale University and AstraZeneca found that very low doses of AZD0328, a novel drug that acts as an alpha-7 agonist, produced both acute and persistent improvements in their performance on a spatial working memory task.

"Our work demonstrates that that the neuronal nicotinic alpha-7 receptor plays a critical role in the core cognitive function of working memory, which is a key indicator of outcome in patients with schizophrenia," explained Dr. Williams. "The function of the alpha-7 receptor may account for the ability of a partial agonist to induce long-term beneficial changes for high-order cognition at such low doses."

This influence on cortical function has been exemplified by the work of Jason Tregellas and colleagues. These researchers examined the effects of DMXB-A, a novel alpha-7 partial agonist, on the brain's 'default network' in people with schizophrenia. Function of the default network, which is likely a major contributor to the intrinsic neuronal activity that accounts for 60-80% of the brain's energy use, is different in people with schizophrenia.

Dr. Tregellas summarized their findings: "We found that DMXB-A altered default network activity in people with schizophrenia in a pattern consistent with improved function of the network. We also found that these neuronal differences were related to the genotype of the alpha-7 nicotinic receptor and to drug-related improvements in symptoms."

Together, "these two studies provide additional support for a novel pharmacologic approach to treat cognitive impairments in schizophrenia", observed Dr. John Krystal, Editor of Biological Psychiatry.


'/>"/>

Contact: Chris J. Pfister
C.Pfister@elsevier.com
215-239-3266
Elsevier
Source:Eurekalert

Related medicine news :

1. Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and Roche
2. Targeting leukemia cells gene addiction presents new strategy for treatment
3. Americans for Responsible Health Care Launch Radio Ads Targeting Seven Democrats, Warning The People Are Watching...
4. Targeting blood vessels, immune system may offer way to stop infection-caused inflammation
5. Diversinet Extends Reach of Mobile Healthcare Information With New Product Release Targeting Healthcare Organizations
6. Targeting cell pathway may prevent relapse of leukemia
7. Age Management Leader Goes Beyond 2010 NANES Study Reqs, Targeting Heightened Obesity Group, Adult 40+
8. New Study on Elder Care Marketing Reveals Fresh Insights in Targeting Aging Population
9. Targeting the blood-brain barrier may delay progression of Alzheimers disease
10. Spanish gene expression data promise targeting of anti-angiogenesis treatment
11. Targeting disease remission has socio-economic benefits over low disease activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , ... December 07, 2016 , ... ... Medicine will have the unique opportunity to get hands-on experience in an ... school students an immersive experience to gain invaluable, real-life medical skills that are ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... drug in their bodies, a researcher at the Icahn School of Medicine at ... , The study found that when young children are exposed to secondhand marijuana ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... a women growing up with a schizophrenic mother in a unique, personal perspective ... who specializes in treating trauma and addictive disorders at her private psychotherapy practice. ...
(Date:12/7/2016)... ... December 07, 2016 , ... It is vital for any lab to ... analyzed data. The team at Beckman Coulter has designed Kaluza, templates with advanced analytical ... the need to operate in a GLP (Good Laboratory Practice) fashion. , With features ...
(Date:12/7/2016)... ... December 07, 2016 , ... Levels of a protein ... according to a study appearing online in the journal Radiology. , Heart disease and ... increase significantly due to the rapidly aging population. Damage to both organs often occurs ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Research and Markets has announced the addition of the ... ... The global chromatography market to grow at a CAGR of 5.42% during ... prepared based on an in-depth market analysis with inputs from industry experts. ... coming years. The report also includes a discussion of the key vendors ...
(Date:12/8/2016)... 2016 According to a ... Product (Actual Sugars, Sugar Alcohols, Artificial Sweeteners), Type ... Agents), Formulation (Oral, Topical, Parenteral) - Global Forecast ... witnessed healthy growth during the last decade, and ... 4.3% between 2016 and 2021 to reach USD ...
(Date:12/8/2016)... SAN FRANCISCO, Calif. , Dec. 8, 2016 ... nuclease technology to develop novel antiviral therapeutics, today ... M.D., as chief executive officer and a member ... is an incredibly experienced executive with a deep ... said Stephen Quake, D.Phil., founder of Agenovir, co-president ...
Breaking Medicine Technology: